PF 07853578
Alternative Names: PF-07853578Latest Information Update: 19 Dec 2023
At a glance
- Originator Pfizer
- Class Hepatoprotectants; Small molecules
- Mechanism of Action Adiponutrin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis
Most Recent Events
- 01 Dec 2023 Pfizer completes a phase-I clinical trials in Non-alcoholic steatohepatitis (In volunteers) in USA (PO) (NCT05890105)
- 14 Jun 2023 Pfizer plans a phase I trial in Healthy volunteers (PO) in June 2023 (NCT05890105)
- 02 Jun 2023 Phase-I clinical trials in Non-alcoholic steatohepatitis (In volunteers) in USA (PO) (NCT05890105)